PerkinElmer Webinar: Cancer Immunology – Charting the Course Forward for Immunoprofiling
Date: Wednesday, April 1, 2015
Time: 12 noon Eastern, 9 a.m. Pacific, 5 p.m. UK (BST), 6 p.m. Central Europe (CEST)
How cells behave in the body depends on numerous factors. Interactions with other cells, through direct contact or via various dissolved factors, are especially important. These interactions not only enable cell survival, but also influence fundamental cellular properties and behaviors. Cancer cells, although aberrant in many respects, are still influenced by their cellular milieu. In fact, associations of cancer cells with the normal peritumoral microenvironment can profoundly impact tumor growth and development.
New technologies are coming to the fore that allow interrogation of the types of cells interacting with tumors, in particular providing intelligence on the broad variety of complex associations between tumor cells and the immune system. The depth and breadth of information obtained is promoting biomarker discovery, especially potential targets for drug therapies, as well as possibly enabling improved patient stratification for clinical trials and treatment protocols. Understanding how to obtain this data and how best to use it is critical for future advances in research and cancer treatment.
Join our Live Webinar to Learn about:
- The latest approaches to immune profiling using FFPE tissue sections, multiplexed IF, and cell phenotyping software
- Developing robust biomarkers for stratifying patients for clinical trials and for optimized treatment
- Technologies and methods for automating and standardizing multiplexed IHC methods
Speaker: Bernard A. Fox, Ph.D., Providence Portland Medical Center
Dr. Fox is an internationally recognized expert on cancer immunotherapy. He is the Harder Family Chair for Cancer Research, Member and Chief, Laboratory of Molecular and Tumor Immunology, at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center. He is also co-founder, president, and CEO of UbiVac, a clinical-stage biotech, and UbiVac-CMV, an R&D-stage biotech. He is also a member and co-leader of the Tumor Immunology Focus Panel for the NCI-designated Knight Cancer Institute and adjunct faculty member, Department of Molecular Microbiology and Immunology, Oregon Health and Science University.
Have the opportunity to ask questions of our expert panel, live during the broadcast
Speaker: Clifford Hoyt, PerkinElmer, Inc.
Mr. Hoyt is a technology strategist in the area of oncology, helping to identify clinical opportunities that can be addressed through new technologies and capabilities. This includes forming collaborations and partnerships with academic and industrial institutions, and managing an applications group on the PerkinElmer, Inc. Hopkinton site to develop methods for analyzing clinical pathology samples. Mr. Hoyt joined PerkinElmer, Inc. through the acquisition of CRI, Inc., of which he was a founder.
Moderator: Sean Sanders, Ph.D. Science/AAAS
Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics.
